Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, 1 Banshandong Road, Hangzhou, 310022, Zhejiang, China.
Cancer Chemother Pharmacol. 2018 Sep;82(3):505-510. doi: 10.1007/s00280-018-3640-6. Epub 2018 Jul 9.
The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC).
The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent chemoradiotherapy were collected and reviewed. The overall response, toxicities, progression-free survival and overall survival were analyzed with SPSS software.
The efficacy of treatment was classified as complete remission in 4 cases (10.5%), partial remission in 22 cases (57.9%) and stable disease in 12 cases (31.6%). The objective response rate was 68.4% (26/38). The most common types of hematological toxicities were anemia (65.7%) and leukopenia (57.9%), but all the events were transient. No paclitaxel-induced allergic reactions occurred during the treatment. The median PFS and OS time were 17.0 and 29.0 months.
Liposome-paclitaxel and carboplatin concurrent with radiotherapy showed a significant antitumor effect to LSCC with manageable toxicities. Further clinical investigation are warranted to evaluate the efficacy of this regimen.
本研究旨在评估脂质体紫杉醇联合卡铂同期放化疗治疗局部晚期肺鳞癌（LSCC）的疗效和毒性。
收集并回顾了 38 例接受基于脂质体紫杉醇的同期放化疗治疗的局部晚期 LSCC 患者的临床资料。采用 SPSS 软件分析总缓解率、毒性反应、无进展生存期和总生存期。
治疗疗效评定为完全缓解 4 例（10.5%），部分缓解 22 例（57.9%），稳定 12 例（31.6%）。客观缓解率为 68.4%（26/38）。最常见的血液学毒性为贫血（65.7%）和白细胞减少（57.9%），但均为一过性。治疗过程中未发生紫杉醇过敏反应。中位 PFS 和 OS 时间分别为 17.0 个月和 29.0 个月。
脂质体紫杉醇联合卡铂同期放化疗对 LSCC 具有显著的抗肿瘤作用，毒性可耐受。需要进一步的临床研究来评估该方案的疗效。
